Nasal Spray Treatment for Diabetic Gastroparesis Eliminates Need to Digest a Pill with Matt D'Onofrio Evoke Pharma

Matt D'Onofrio, Co-Founder, President, and Chief Operating Officer at Evoke Pharma, is developing a treatment to help patients with diabetic gastroparesis.  This little-known disease is thought to be due to damage to the vagus nerve, interrupting the communication between the brain and gut, stopping the stomach from functioning normally. Current treatments are a pill required to move through the stomach.  Evoke has developed a nasal spray to treat the condition that bypasses the stomach and provides predictable relief. Matt explains, "We developed a product called GIMOTI, or nasal metoclopramide. The interest behind doing so is to completely bypass the stomach to get a dose on board for patients. The unpredictable nature of the stomach makes dosing with pills very unpredictable. We know that a number of patients who take oral treatments don't find efficacy. We believe that's, in part, because of the stomach's problems itself." "By developing the nasal format, or GIMOTI, we are able to avoid that unpredictable issue and get the product on board directly by spraying it into the nose and getting absorption straight through the thin membrane in your nostrils, getting the product into the bloodstream from there. We found that this is very helpful for patients who do have issues with any absorption problems. We also found it helpful for patients who are nauseated and vomiting because you can't vomit up a nasal spray. There have been a number of different things we found as the product has come on the market that's been helpful for it." #EVOK #Evoke #FightGastroparesis #DGPAwareness #DiabeticGastroparesis  evokepharma.com Download the transcript here